Anti-HER2 Nanobody Labeled with 225Ac as a Potential Radiopharmaceutical for TRT

Human epidermal growth factor receptor type 2 (HER2) is overexpressed in breast, ovarian, non-small cell lung, gastric and colon cancers, and portends poor prognosis. Intact mAbs are not always ideal vectors for radioimmunotherapy due to their slow pharmacokinetic and normal-tissue clearance. Nanobodies (Nbs) are single domain antibodies derived from Camelidae. Their small size (~15kDa), nM-range affinity, low immunogenicity, rapid clearance from blood and normal tissues and ease of tumor penetration make them a very attractive platform for targeted radionuclide therapy (TRT). The goal of this study was to develop and characterize a potential molecular-targeted drug based on the anti-HER2-Nb labeled with 225Ac

PRUSZYNSKI Marek;  LESZCZUK Edyta;  RADCHENKO Valery;  JOHN Kevin Dale;  BRUCHERTSEIFER Frank;  MORGENSTERN Alfred;  D’HUYVETTER Matthias;  LAHOUTTE Tony; 

2016-11-17

SPRINGER

JRC101405

1619-7070,   

https://publications.jrc.ec.europa.eu/repository/handle/JRC101405,   

10.1007/s00259-016-3484-4,